Agenus pointing to its checkpoint inhibitors

Agenus Inc. (NASDAQ:AGEN) is looking past the demise of its Prophage G-200 vaccine in brain cancer and pointing investors to upcoming milestones for its checkpoint

Read the full 252 word article

How to gain access

Continue reading with a
two-week free trial.